EP1543109A4 - Substanzen zur vorbeugung und behandlung von autoimmunkrankheiten - Google Patents

Substanzen zur vorbeugung und behandlung von autoimmunkrankheiten

Info

Publication number: EP1543109A4
Authority: EP; European Patent Office
Prior art keywords: preventing; substances; autoimmune diseases; autoimmune disease; treating autoimmune
Prior art date: 2002-08-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP03808948A

Other languages

English (en)

French (fr)

Other versions

EP1543109B1 (de

EP1543109A2 (de

Inventor

Alan P Escher

Fengchun Li

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Loma Linda University

Original Assignee

Loma Linda University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-06

Filing date

2003-08-06

Publication date

2005-10-19

2003-08-06 Application filed by Loma Linda University filed Critical Loma Linda University

2003-08-06 Priority to EP05021002A priority Critical patent/EP1626083B1/de

2003-08-06 Priority to EP05021001A priority patent/EP1624053B1/de

2005-06-22 Publication of EP1543109A2 publication Critical patent/EP1543109A2/de

2005-10-19 Publication of EP1543109A4 publication Critical patent/EP1543109A4/de

2008-02-13 Application granted granted Critical

2008-02-13 Publication of EP1543109B1 publication Critical patent/EP1543109B1/de

2023-08-06 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Biotechnology (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
Biophysics (AREA)
General Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Physics & Mathematics (AREA)
Rheumatology (AREA)
Plant Pathology (AREA)
Toxicology (AREA)
Hematology (AREA)
Mycology (AREA)
Cell Biology (AREA)
Marine Sciences & Fisheries (AREA)
Rehabilitation Therapy (AREA)
Virology (AREA)

EP03808948A 2002-08-06 2003-08-06 Substanzen zur vorbeugung und behandlung von autoimmunkrankheiten Expired - Lifetime EP1543109B1 (de)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
EP05021002A EP1626083B1 (de)	2002-08-06	2003-08-06	Substanzen zur Vorbeugung und Behandlung von Autoimmunkrankheiten
EP05021001A EP1624053B1 (de)	2002-08-06	2003-08-06	Substanzen zur Vorbeugung und Behandlung von Autoimmunkrankheiten

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US40165202P	2002-08-06	2002-08-06
US401652P		2002-08-06
PCT/US2003/024625 WO2004034966A2 (en)	2002-08-06	2003-08-06	Substances for preventing and treating autoimmune diseases

Related Child Applications (2)

Application Number	Title	Priority Date	Filing Date
EP05021001A Division EP1624053B1 (de)	2002-08-06	2003-08-06	Substanzen zur Vorbeugung und Behandlung von Autoimmunkrankheiten
EP05021002A Division EP1626083B1 (de)	2002-08-06	2003-08-06	Substanzen zur Vorbeugung und Behandlung von Autoimmunkrankheiten

Publications (3)

Publication Number	Publication Date
EP1543109A2 EP1543109A2 (de)	2005-06-22
EP1543109A4 true EP1543109A4 (de)	2005-10-19
EP1543109B1 EP1543109B1 (de)	2008-02-13

Family

ID=32107846

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
EP03808948A Expired - Lifetime EP1543109B1 (de)	2002-08-06	2003-08-06	Substanzen zur vorbeugung und behandlung von autoimmunkrankheiten
EP05021002A Expired - Lifetime EP1626083B1 (de)	2002-08-06	2003-08-06	Substanzen zur Vorbeugung und Behandlung von Autoimmunkrankheiten
EP05021001A Expired - Lifetime EP1624053B1 (de)	2002-08-06	2003-08-06	Substanzen zur Vorbeugung und Behandlung von Autoimmunkrankheiten

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
EP05021002A Expired - Lifetime EP1626083B1 (de)	2002-08-06	2003-08-06	Substanzen zur Vorbeugung und Behandlung von Autoimmunkrankheiten
EP05021001A Expired - Lifetime EP1624053B1 (de)	2002-08-06	2003-08-06	Substanzen zur Vorbeugung und Behandlung von Autoimmunkrankheiten

Country Status (10)

Country	Link
US (3)	US7381711B2 (de)
EP (3)	EP1543109B1 (de)
JP (3)	JP4301567B2 (de)
CN (3)	CN100389192C (de)
AT (3)	ATE386104T1 (de)
AU (1)	AU2003296892B2 (de)
CA (3)	CA2649821C (de)
DE (3)	DE60309513T2 (de)
ES (3)	ES2275253T3 (de)
WO (1)	WO2004034966A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2649821C (en) *	2002-08-06	2016-09-20	Loma Linda University	Polynucleotide sequences encoding .delta.bcl-2 for preventing and treating autoimmune diseases
WO2006047954A1 (en) *	2004-11-04	2006-05-11	Ziyi Cheng	The method of obtaining and applying the materials for autoantigen immunological recognition
ES2348701T3 (es) *	2005-05-11	2010-12-10	Loma Linda University	Composiciones y mã‰todos para prevenir y tratar trastornos inflamatorios de mediaciã“n inmune.
US20090191218A1 (en)	2005-05-11	2009-07-30	Fengchun Li	DNA Vaccines And Methods For The Prevention Of Transplantation Rejection
EP2868743B1 (de)	2006-09-28	2017-11-15	Loma Linda University	Durch apoptotische Zellen vermittelte Transfektion von Säugetierzellen mit interferierender RNA
WO2011149593A1 (en)	2010-05-28	2011-12-01	Dow Corning Corporation	Preparation of organohalosilanes
WO2011149588A1 (en)	2010-05-28	2011-12-01	Dow Corning Corporation	A method for preparing a diorganodihalosilane
JP6017422B2 (ja)	2010-08-10	2016-11-02	エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）ＥｃｏｌｅＰｏｌｙｔｅｃｈｎｉｑｕｅＦｅｄｅｒａｌｅｄｅＬａｕｓａｎｎｅ（ＥＰＦＬ）	赤血球結合療法
US9517257B2 (en)	2010-08-10	2016-12-13	Ecole Polytechnique Federale De Lausanne (Epfl)	Erythrocyte-binding therapeutics
US9850296B2 (en)	2010-08-10	2017-12-26	Ecole Polytechnique Federale De Lausanne (Epfl)	Erythrocyte-binding therapeutics
EP2614035A1 (de)	2010-09-08	2013-07-17	Dow Corning Corporation	Verfahren zur herstellung eines trihalosilans
EP2651954B1 (de)	2010-12-17	2015-09-16	Dow Corning Corporation	Verfahren zur herstellung eines trihalosilanes
US10813987B2 (en)	2011-09-23	2020-10-27	Loma Linda University	Method for inducing a tolerogenic immune response
US11680273B2 (en)	2011-09-23	2023-06-20	Loma Linda University	Treatment of autoimmune diseases
IN2015DN01936A (de)	2012-08-13	2015-08-07	Dow Corning
CN103116030A (zh) *	2013-01-30	2013-05-22	山东东兴生物科技股份有限公司	一种检测i型糖尿病自身免疫抗体试剂盒及其检测方法
US9688703B2 (en)	2013-11-12	2017-06-27	Dow Corning Corporation	Method for preparing a halosilane
US10946079B2 (en)	2014-02-21	2021-03-16	Ecole Polytechnique Federale De Lausanne	Glycotargeting therapeutics
KR20240154672A (ko)	2014-02-21	2024-10-25	에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘)	글리코타겟팅 치료제
US10953101B2 (en)	2014-02-21	2021-03-23	École Polytechnique Fédérale De Lausanne (Epfl)	Glycotargeting therapeutics
US10046056B2 (en)	2014-02-21	2018-08-14	École Polytechnique Fédérale De Lausanne (Epfl)	Glycotargeting therapeutics
JP6725510B2 (ja)	2014-12-18	2020-07-22	ダウシリコーンズコーポレーション	アリール官能性シランの製造方法
EP3638296A1 (de)	2017-06-16	2020-04-22	The University Of Chicago	Zusammensetzungen und verfahren zur herbeiführung einer immuntoleranz
WO2019028503A1 (en) *	2017-08-07	2019-02-14	St Vincent's Institute Of Medical Research	THERAPY OF DIABETES TYPE 1
SG11202011078VA (en)	2018-05-09	2020-12-30	Univ Chicago	Compositions and methods concerning immune tolerance
CA3174524A1 (en) *	2020-03-03	2021-09-10	Aditxt, Inc.	Methods of treating hyperglycemia and suppressing onset of type 1 diabetes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000059538A2 (en) *	1999-04-08	2000-10-12	The John Hopkins University	Antigen-specific induction of peripheral immune tolerance

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5700638A (en) *	1993-08-26	1997-12-23	Washington University	Cell death regulator
US5691179A (en) *	1993-08-26	1997-11-25	Washington University	Cell death regulators
CN1056380C (zh) *	1998-02-27	2000-09-13	中科院成都地奥制药公司	抑制人体恶性肿瘤生长的反义寡核苷酸
US6645490B2 (en) *	1998-03-02	2003-11-11	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
JP2000236100A (ja) *	1999-02-17	2000-08-29	Sanyo Electric Co Ltd	半導体素子
CN1117098C (zh) *	1999-06-25	2003-08-06	北京金赛狮生物制药技术开发有限责任公司	针对囊依赖的淋巴细胞白血病基因的反义核酸的抑癌作用
CA2649821C (en) *	2002-08-06	2016-09-20	Loma Linda University	Polynucleotide sequences encoding .delta.bcl-2 for preventing and treating autoimmune diseases

2003
- 2003-08-06 CA CA2649821A patent/CA2649821C/en not_active Expired - Lifetime
- 2003-08-06 DE DE60309513T patent/DE60309513T2/de not_active Expired - Lifetime
- 2003-08-06 CN CNB038190087A patent/CN100389192C/zh not_active Expired - Fee Related
- 2003-08-06 EP EP03808948A patent/EP1543109B1/de not_active Expired - Lifetime
- 2003-08-06 AT AT03808948T patent/ATE386104T1/de not_active IP Right Cessation
- 2003-08-06 DE DE60309514T patent/DE60309514T2/de not_active Expired - Lifetime
- 2003-08-06 JP JP2004545230A patent/JP4301567B2/ja not_active Expired - Fee Related
- 2003-08-06 ES ES05021001T patent/ES2275253T3/es not_active Expired - Lifetime
- 2003-08-06 CN CN2007100979587A patent/CN101147807B/zh not_active Expired - Fee Related
- 2003-08-06 ES ES03808948T patent/ES2300652T3/es not_active Expired - Lifetime
- 2003-08-06 DE DE60319103T patent/DE60319103T2/de not_active Expired - Lifetime
- 2003-08-06 EP EP05021002A patent/EP1626083B1/de not_active Expired - Lifetime
- 2003-08-06 AT AT05021002T patent/ATE344317T1/de not_active IP Right Cessation
- 2003-08-06 CA CA002494888A patent/CA2494888C/en not_active Expired - Lifetime
- 2003-08-06 WO PCT/US2003/024625 patent/WO2004034966A2/en not_active Ceased
- 2003-08-06 CA CA2653201A patent/CA2653201C/en not_active Expired - Lifetime
- 2003-08-06 AU AU2003296892A patent/AU2003296892B2/en not_active Expired
- 2003-08-06 ES ES05021002T patent/ES2275254T3/es not_active Expired - Lifetime
- 2003-08-06 US US10/523,655 patent/US7381711B2/en not_active Expired - Lifetime
- 2003-08-06 AT AT05021001T patent/ATE344316T1/de not_active IP Right Cessation
- 2003-08-06 EP EP05021001A patent/EP1624053B1/de not_active Expired - Lifetime
- 2003-08-06 CN CN2007100979572A patent/CN101057976B/zh not_active Expired - Fee Related
2007
- 2007-08-09 US US11/836,640 patent/US20080171713A1/en not_active Abandoned
- 2007-08-09 US US11/836,661 patent/US7638498B2/en not_active Expired - Lifetime
2009
- 2009-02-06 JP JP2009025647A patent/JP5555431B2/ja not_active Expired - Fee Related
- 2009-02-06 JP JP2009025648A patent/JP5123226B2/ja not_active Expired - Fee Related

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000059538A2 (en) *	1999-04-08	2000-10-12	The John Hopkins University	Antigen-specific induction of peripheral immune tolerance

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FILIPPOVA M ET AL: "Effects of plasmid DNA injection on cyclophosphamide-accelerated diabetes in NOD mice", DNA AND CELL BIOLOGY, NEW YORK, NY, US, vol. 20, no. 3, 1 March 2001 (2001-03-01), pages 175 - 181, XP002295859, ISSN: 1044-5498 *
LI A F ET AL: "Co-delivery of pro-apoptotic BAX with a DNA vaccine recruits dendritic cells and promotes efficacy of autoimmune diabetes prevention in mice", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 22, no. 13-14, 16 April 2004 (2004-04-16), pages 1751 - 1763, XP004500430, ISSN: 0264-410X *
TOKUI M ET AL: "Studies on the Prevention of Diabetes in NOD Mice by Intramuscular Administration of Plasmid Expressing GAD and IL-4", CHEMICAL ABSTRACTS + INDEXES, AMERICAN CHEMICAL SOCIETY. COLUMBUS, US, vol. 25, no. 125, 1996, pages 1148, XP002086509, ISSN: 0009-2258 *

Also Published As

Publication number	Publication date
JP2006513993A (ja)	2006-04-27
CA2653201C (en)	2011-11-08
JP2009149664A (ja)	2009-07-09
CN1675353A (zh)	2005-09-28
DE60309513D1 (de)	2006-12-14
US7638498B2 (en)	2009-12-29
JP5123226B2 (ja)	2013-01-23
US7381711B2 (en)	2008-06-03
ES2275253T3 (es)	2007-06-01
EP1624053A1 (de)	2006-02-08
DE60309514T2 (de)	2007-05-10
JP5555431B2 (ja)	2014-07-23
US20050239729A1 (en)	2005-10-27
EP1626083B1 (de)	2006-11-02
EP1626083A1 (de)	2006-02-15
DE60309514D1 (de)	2006-12-14
WO2004034966A2 (en)	2004-04-29
WO2004034966A3 (en)	2004-07-08
AU2003296892B2 (en)	2006-01-05
ATE344316T1 (de)	2006-11-15
JP2009143945A (ja)	2009-07-02
ATE344317T1 (de)	2006-11-15
ES2275254T3 (es)	2007-06-01
CA2649821C (en)	2016-09-20
AU2003296892A1 (en)	2004-05-04
DE60319103T2 (de)	2009-02-05
EP1543109B1 (de)	2008-02-13
ATE386104T1 (de)	2008-03-15
CN100389192C (zh)	2008-05-21
CN101057976B (zh)	2010-05-26
DE60319103D1 (de)	2008-03-27
US20080171714A1 (en)	2008-07-17
EP1624053B1 (de)	2006-11-02
CA2494888C (en)	2009-03-31
CN101147807A (zh)	2008-03-26
CN101057976A (zh)	2007-10-24
JP4301567B2 (ja)	2009-07-22
CA2653201A1 (en)	2004-04-29
CA2494888A1 (en)	2004-04-29
CN101147807B (zh)	2010-05-26
EP1543109A2 (de)	2005-06-22
CA2649821A1 (en)	2004-04-29
US20080171713A1 (en)	2008-07-17
ES2300652T3 (es)	2008-06-16
DE60309513T2 (de)	2007-05-03

Legal Events

Date	Code	Title	Description
2005-05-06	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2005-06-22	17P	Request for examination filed	Effective date: 20050216
2005-06-22	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR
2005-06-22	AX	Request for extension of the european patent	Extension state: AL LT LV MK
2005-10-19	A4	Supplementary search report drawn up and despatched	Effective date: 20050905
2005-11-23	DAX	Request for extension of the european patent (deleted)
2006-09-20	R17P	Request for examination filed (corrected)	Effective date: 20050216
2007-04-04	17Q	First examination report despatched	Effective date: 20070302
2007-07-11	17Q	First examination report despatched	Effective date: 20070302
2007-10-02	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2007-11-01	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2007-11-14	RIN1	Information on inventor provided before grant (corrected)	Inventor name: ESCHER, ALAN, P. Inventor name: LI, FENGCHUN
2008-01-11	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2008-02-13	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR
2008-02-13	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2008-02-29	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2008-03-19	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2008-03-27	REF	Corresponds to:	Ref document number: 60319103 Country of ref document: DE Date of ref document: 20080327 Kind code of ref document: P
2008-03-27	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 60319103 Country of ref document: DE Effective date: 20080327
2008-06-16	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2300652 Country of ref document: ES Kind code of ref document: T3
2008-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080213
2008-08-01	NLV1	Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
2008-08-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080213
2008-09-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080213 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080213
2008-10-17	ET	Fr: translation filed
2008-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080213 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080513 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080213 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080213 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080714 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080213
2008-11-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080213
2008-12-19	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2008-12-19	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2009-01-21	26N	No opposition filed	Effective date: 20081114
2009-03-12	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 60319103 Country of ref document: DE Effective date: 20081114
2009-03-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080831
2009-03-31	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2009-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080213 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080513
2009-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080831 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080831
2009-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080213 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080806
2010-07-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080806 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080814
2010-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080213
2010-10-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080514
2016-08-25	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 14
2017-08-25	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 15
2019-08-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180831
2019-08-30	PGRI	Patent reinstated in contracting state [announced from national office to epo]	Ref country code: FR Effective date: 20190514
2022-10-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IT Payment date: 20220819 Year of fee payment: 20 Ref country code: GB Payment date: 20220829 Year of fee payment: 20 Ref country code: ES Payment date: 20220901 Year of fee payment: 20 Ref country code: DE Payment date: 20220829 Year of fee payment: 20
2022-11-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20220825 Year of fee payment: 20
2023-06-21	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230516
2023-08-06	REG	Reference to a national code	Ref country code: DE Ref legal event code: R071 Ref document number: 60319103 Country of ref document: DE
2023-08-25	REG	Reference to a national code	Ref country code: ES Ref legal event code: FD2A Effective date: 20230825
2023-08-30	REG	Reference to a national code	Ref country code: GB Ref legal event code: PE20 Expiry date: 20230805
2023-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20230805 Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20230807

Publication	Publication Date	Title
ATE344317T1 (de)	2006-11-15	Substanzen zur vorbeugung und behandlung von autoimmunkrankheiten
DK1368060T3 (da)	2010-08-30	HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
FI963101A7 (fi)	1996-08-06	Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoo n, joissa seerumin interleukiini-6-taso on kohonnut
EE04156B1 (et)	2003-10-15	Sulfoonamiidid endoteliini vahendatud haiguste ravimiseks
PL2356996T3 (pl)	2013-09-30	Leczenie choroby Alzheimera
EE200300214A (et)	2003-08-15	Sulfoonamiidid endoteliini vahendatud haiguste ravimiseks
ATE444967T1 (de)	2009-10-15	Spezifische bindungsmittel von human angiopoietin-2
ATE472325T1 (de)	2010-07-15	Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
NO20031218L (no)	2003-05-19	Kombinasjonsterapi for behandling av autoimmunsykdommer ved anvendelse av B-cellereduserende immunregulerende antistoff kombinasjon
DE60325209D1 (de)	2009-01-22	Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
DE3856180D1 (de)	1998-06-18	Nukleinsaürefragmente, die mannose bindende fragmente vom menschlichen mannosebindenden protein kodieren
MXPA03008739A (es)	2003-12-11	Anticuerpos recombinantes asociados a gangliosidos. su uso en el diagnostico y tratamiento de tumores.
WO2003062273A3 (en)	2003-08-28	Modulator of the notch signalling pathway and use thereof in medical treatment
DE50013843D1 (de)	2007-01-18	Arzneimittel zur behandlung von darmerkrankungen
DE602004020266D1 (de)	2009-05-07	Therapeutische und diagnostische anti-hsp 70-antikörper
DE60304695D1 (de)	2006-05-24	7-ARYLSULFONAMID-2,3,4,5-TETRAHYDRO-1H-BENZOiDöAZEPINE MIT 5-HT6 REZEPTOR AFFINITÄT ZUR BEHANDLUNG VON ZENTRALNERVENSYSTEMERKRANKUNGEN
ATE491442T1 (de)	2011-01-15	1-phenyl-2- dimethylaminomethylcyclohexanverbindungen zur therapie von depressiven symptomatiken, schmerz und inkontinenz
ATE265225T1 (de)	2004-05-15	Pharmazeutische präparation, enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen
ATE343387T1 (de)	2006-11-15	S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen.
ATE537257T1 (de)	2011-12-15	Mit iga-nephropathie assoziierte dns
WO2002088345A3 (en)	2003-08-28	Murine dnasex, medicament containing the same and non-human mammal comprising modified dnasex gene
ATE297745T1 (de)	2005-07-15	Chemische modifizierung von harn von säugern
TR199700062U (tr)	1997-04-22	Tek kullanimlik hijyenik terlik ve tabanlik.